Sat, Jul 26, 2014, 11:11 AM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • thirdmeinvestor thirdmeinvestor Feb 26, 2008 12:59 PM Flag

    analysts are a joke

    I don't remember SGP disclosing whether or not their numbers were on the ITT basis, but it is most likely that your thinking is correct.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • here is the data from SGP:

      "In the treatment-naive study, known as HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1), boceprevir (800 mg TID) is being evaluated in three treatment regimens: in combination with PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily) for 28 or 48 weeks; 4 weeks of PEGINTRON and REBETOL combination therapy at the doses described above followed by adding boceprevir to the combination for 24 or 44 weeks; and boceprevir in combination with PEGINTRON and low-dose REBETOL (400-1000 mg daily) for 48 weeks, compared to a control of PEGINTRON and REBETOL alone for 48 weeks (a standard of care). The primary endpoint of this study is sustained virologic response. Patients receiving these boceprevir regimens achieved a high rate of early virologic response, with 70, 79 and 54 percent of patients, respectively, having undetectable virus (HCV-RNA) at week 12 of boceprevir therapy compared to 34 percent of patients in the control arm (Roche Cobas Taqman 1.0 assay; lower limit of detection is 15 IU/mL). Treatment discontinuations due to adverse events were 12, 9, and 8 percent for patients in the boceprevir regimens, respectively, compared to 5 percent for the control arm."

      It says the data is based on "patients receiving these Broceprevir regiments..." which to me indicates those who discontinued before completing the regiments were excluded from the statistics. Looking at it another way nowhere did they indicate inclusion of discontinued patients in their calculations whereas VRTX went to great length to indicate that they were all counted as failures.

      The other difference is that TVR limit of detection was 10 IU/mL as opposed to SGP's 15 IU/mL.

95.75-0.02(-0.02%)Jul 25 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.